Idiopathic thrombocytopenic purpura
|Idiopathic thrombocytopenic purpura|
|Classification and external resources|
Petechiae, or small bruise-like markings, may occur in ITP
|Patient UK||Idiopathic thrombocytopenic purpura|
Idiopathic thrombocytopenic purpura (ITP), also known as immune thrombocytopenia, primary immune thrombocytopenia, primary immune thrombocytopenic purpura or autoimmune thrombocytopenic purpura, is defined as isolated low platelet count (thrombocytopenia) with normal bone marrow and the absence of other causes of thrombocytopenia. It causes a characteristic purpuric rash and an increased tendency to bleed. Two distinct clinical syndromes manifest as an acute condition in children and a chronic condition in adults. The acute form often follows an infection and has a spontaneous resolution within 2 months. Chronic idiopathic thrombocytopenic purpura persists longer than 6 months with a specific cause being unknown.
ITP is diagnosed by a low platelet count in a complete blood count (a common blood test). However, since the diagnosis depends on the exclusion of other causes of a low platelet count, additional investigations (such as a bone marrow biopsy) may be necessary in some cases.
In mild cases, only careful observation may be required but very low counts or significant bleeding may prompt treatment with corticosteroids, intravenous immunoglobulin, anti-D immunoglobulin, or immunosuppressive drugs. Refractory ITP (not responsive to conventional treatment) may require splenectomy, the surgical removal of the spleen. Platelet transfusions may be used in severe bleeding together with a very low count. Sometimes the body may compensate by making abnormally large platelets.
- 1 Signs and symptoms
- 2 Pathogenesis
- 3 Diagnosis
- 4 Treatment
- 5 Epidemiology
- 6 Pregnancy
- 7 History
- 8 References
- 9 External links
Signs and symptoms
Signs include the spontaneous formation of bruises (purpura) and petechiae (tiny bruises), especially on the extremities, bleeding from the nostrils and/or gums, and menorrhagia (excessive menstrual bleeding), any of which may occur if the platelet count is below 20,000 per μl. A very low count (<10,000 per μl) may result in the spontaneous formation of hematomas (blood masses) in the mouth or on other mucous membranes. Bleeding time from minor lacerations or abrasions is usually prolonged.
Serious and possibly fatal complications due to extremely low counts (<5,000 per μl) include subarachnoid or intracerebral hemorrhage (bleeding inside the skull or brain), lower gastrointestinal bleeding or other internal bleeding. An ITP patient with an extremely low count is vulnerable to internal bleeding caused by blunt abdominal trauma, as might be experienced in a motor vehicle crash. These complications are not likely when the platelet count is above 20,000 per μl.
In approximately 60 percent of cases, antibodies against platelets can be detected. Most often these antibodies are against platelet membrane glycoproteins IIb-IIIa or Ib-IX, and are of the immunoglobulin G (IgG) type. Some renowned research, the Harrington–Hollingsworth experiment, established the immune pathogenesis of ITP.
The coating of platelets with IgG renders them susceptible to opsonization and phagocytosis by splenic macrophages, as well by Kupffer cells in the liver. The IgG autoantibodies are also thought to damage megakaryocytes, the precursor cells to platelets, although this is believed to contribute only slightly to the decrease in platelet numbers. Recent research now indicates that impaired production of the glycoprotein hormone thrombopoietin, which is the stimulant for platelet production, may be a contributing factor to the reduction in circulating platelets. This observation has led to the development of a class of ITP-targeted drugs referred to as thrombopoietin receptor agonists.
The stimulus for auto-antibody production in ITP is probably abnormal T cell activity. Preliminary findings suggest that these T cells can be influenced by drugs that target B cells, such as rituximab.
The diagnosis of ITP is a process of exclusion. First, it has to be determined that there are no blood abnormalities other than a low platelet count, and no physical signs other than bleeding. Then, secondary causes (5–10 percent of suspected ITP cases) should be excluded. Such secondary causes include leukemia, medications (e.g., quinine, heparin), lupus erythematosus, cirrhosis, HIV, hepatitis C, congenital causes, antiphospholipid syndrome, von Willebrand factor deficiency, onyalai and others. In approximately one percent of cases, autoimmune hemolytic anemia and ITP coexist, a condition referred to as Evans syndrome, a condition that points to CLL as a possible cause.
Despite the destruction of platelets by splenic macrophages, the spleen is normally not enlarged. In fact, an enlarged spleen should lead to a search for other possible causes for the thrombocytopenia. Bleeding time is usually prolonged in ITP patients. However, the use of bleeding time in diagnosis is discouraged by the American Society of Hematology practice guidelines and a normal bleeding time does not exclude a platelet disorder.
Bone marrow examination may be performed on patients over the age of 60 and those who do not respond to treatment, or when the diagnosis is in doubt. On examination of the marrow, an increase in the production of megakaryocytes may be observed and may help in establishing a diagnosis of ITP. An analysis for anti-platelet antibodies is a matter of clinician's preference, as there is disagreement on whether the 80 percent specificity of this test is sufficient to be clinically useful.
With rare exceptions, there is usually no need to treat based on platelet counts. Many older recommendations suggested a certain platelet count threshold (usually somewhere below 20.0/µl) as an indication for hospitalisation or treatment. Current guidelines recommend treatment only in cases of significant bleeding. Treatment recommendations sometimes differ for adult and pediatric ITP.
Initial treatment usually consists of the administration of corticosteroids, a group of medications that suppress the immune system. The dose and mode of administration is determined by platelet count and whether there is active bleeding: in urgent situations, infusions of dexamethasone or methylprednisolone may be used, while oral prednisone or prednisolone may suffice in less severe cases. Once the platelet count has improved, the dose of steroid is gradually reduced while the possibility of relapse is monitored. 60–90 percent will experience a relapse during dose reduction or cessation. Long-term steroids are avoided if possible because of potential side-effects that include osteoporosis, diabetes and cataracts.
Another option, suitable for Rh-positive, non-splenectomized patients is intravenous administration of Rho(D) immune globulin [Human; Anti-D]. The mechanism of action of anti-D is not fully understood. However, following administration, anti-D-coated red blood cell complexes saturate Fcγ receptor sites on macrophages, resulting in preferential destruction of red blood cells (RBCs), therefore sparing antibody-coated platelets. There are two anti-D products indicated for use in patients with ITP: WinRho SDF and Rhophylac. The commonest adverse reactions are headache (2%), chills (<2%) and fever (1%).
There is increasing use of Immunosuppresants such as mycophenolate mofetil and azathioprine because of their effectiveness. In chronic refractory cases, where immune pathogenesis has been confirmed, the off-label use of vincristine, a chemotherapy agent, may be attempted. However, this vinca alkaloid, has significant side-effects and its use in treating ITP must be approached with caution, especially in children.
Intravenous immunoglobulin (IVIg) may be infused in some cases. However, while sometimes effective, it is costly and produces improvement that generally lasts less than a month. Nevertheless, in the case of an ITP patient already scheduled for surgery who has a dangerously low platelet count and has experienced a poor response to other treatments, IVIg can increase the count and reduce bleeding risk.
Thrombopoietin receptor agonists
Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction. Two such products are currently available:
- Romiplostim (trade name Nplate) is a thrombopoiesis stimulating Fc-peptide fusion protein (peptibody) that is administered by subcutaneous injection. Designated an orphan drug in 2003 under USA law, clinical trials demonstrated romiplostim to be effective in treating chronic ITP, especially in relapsed post-splenectomy patients. Romiplostim was approved by the United States Food and Drug Administration (FDA) for long-term treatment of adult chronic ITP on August 22, 2008.
- Eltrombopag (trade name Promacta in the USA, Revolade in the EU) is an orally-administered agent with an effect similar to that of romiplostim. It too has been demonstrated to increase platelet counts and decrease bleeding in a dose-dependent manner. Developed by GlaxoSmithKline and also designated an orphan drug by the FDA, Promacta was approved by the FDA on November 20, 2008.
Side effects of thrombopoietin receptor agonists include headache, joint or muscle pain, dizziness, nausea or vomiting, and an increased risk of blood clots.
Splenectomy (removal of the spleen) may be considered, as platelets which have been bound by antibodies are taken up by macrophages in the spleen (which have Fc receptors). The procedure is potentially risky in ITP cases due to the increased possibility of significant bleeding during surgery. Durable remission following splenectomy is achieved in 60 to 65 percent of ITP cases, less so in older subjects. As noted in the introduction, the use of splenectomy to treat ITP has diminished since the development of steroid therapy and other pharmaceutical remedies.
Platelet transfusion alone is normally not recommended except in an emergency, and is usually unsuccessful in producing a long-term platelet count increase. This is because the underlying autoimmune mechanism that is destroying the patient's platelets will also destroy donor platelets.
H. pylori eradication
In adults, particularly those living in areas with a high prevalence of Helicobacter pylori (which normally inhabits the stomach wall and has been associated with peptic ulcers), identification and treatment of this infection has been shown to improve platelet counts in a third of patients. In a fifth, the platelet count normalized completely; this response rate is similar to that found in treatment with rituximab, which is more expensive and less safe. In children, this approach is not supported by evidence, except in high prevalence areas. Urea breath testing and stool antigen testing perform better than serology-based tests; moreover, serology may be false-positive after treatment with IVIG.
Experimental and novel agents
- Dapsone (also called diphenylsulfone, DDS, or avlosulfon) is an anti-infective sulfone drug. In recent years, Dapsone has also proved helpful in treating lupus, rheumatoid arthritis and has had some application as a second-line treatment for ITP. The exact mechanism by which Dapsone assists in ITP is unclear. However, limited studies report successful increases in platelet counts in 40–50 percent of patients administered the drug.
- The off-label use of rituximab, a chimeric monoclonal antibody against the B cell surface antigen CD20, has been shown in preliminary studies to be an effective alternative to splenectomy in some patients. However, many patients experience significant side-effects, there is a small risk of fatality due to progressive multifocal leukoencephalopathy caused by a reactivated JC virus, and randomized controlled trials have yet to be conducted.
- Promising results have been reported in a small phase II study of the experimental kinase inhibitor tamatinib fosdium (R788). In a population of 14 patients refractory to other treatments (ten of them having relapsed following splenectomy), nine responded to tamatinib and six achieved platelet counts greater than 100,000.
A normal platelet count is considered to be in the range of 150,000–450,000 per microlitre (μl) of blood for most healthy individuals. Hence one may be considered thrombocytopenic below that range, although the threshold for a diagnosis of ITP is not tied to any specific number.
The incidence of ITP is estimated at 50–100 new cases per million per year, with children accounting for half of that amount. At least 70 percent of childhood cases will end up in remission within six months, even without treatment. Moreover, a third of the remaining chronic cases will usually remit during follow-up observation, and another third will end up with only mild thrombocytopenia (defined as a platelet count above 50,000). A number of immune related genes and polymorphisms have been identified as influencing predisposition to ITP, with FCGR3a-V158 allele and KIRDS2/DL2 increasing susceptibility and KIR2DS5 shown to be protective.
ITP is usually chronic in adults and the probability of durable remission is 20–40 percent. The male to female ratio in the adult group varies from 1:1.2 to 1.7 in most age ranges (childhood cases are roughly equal for both genders) and the median age of adults at the diagnosis is 56–60. The ratio between male and female adult cases tends to widen with age. In the USA, the adult chronic population is thought to be approximately 60,000—with women outnumbering men approximately 2 to 1, which has resulted in ITP being designated an orphan disease.
The mortality rate due to chronic ITP varies but tends to be higher relative to the general population for any age range. In a study conducted in Great Britain, it was noted that ITP causes an approximately 60 percent higher rate of mortality compared to gender- and age-matched subjects without ITP. This increased risk of death with ITP is largely concentrated in the middle-aged and elderly. Ninety-six percent of reported ITP-related deaths were individuals 45 years or older. No significant difference was noted in the rate of survival between males and females.
Anti-platelet autoantibodies in a pregnant woman with ITP will attack the patient's own platelets and will also cross the placenta and react against fetal platelets. Therefore, ITP is a significant cause of fetal and neonatal immune thrombocytopenia. Approximately 10% of newborns affected by ITP will have platelet counts <50,000/uL and 1% to 2% will have a risk of intracerebral hemorrhage comparable to infants with neonatal alloimmune thrombocytopenia (NAIT).
No lab test can reliably predict if neonatal thrombocytopenia will occur. The risk of neonatal thrombocytopenia is increased with:
- Mothers with a history of splenectomy for ITP
- Mothers who had a previous infant affected with ITP
- Gestational (maternal) platelet count less than 100,000/uL
It is recommended that mothers with thrombocytopenia or a previous diagnosis of ITP should be tested for serum antiplatelet antibodies. A woman with symptomatic thrombocytopenia and an identifiable antiplatelet antibody should be started on therapy for their ITP which may include steroids or IVIG. Fetal blood analysis to determine the platelet count is not generally performed as ITP-induced thrombocytopenia in the fetus is generally less severe than NAIT. Platelet transfusions may be performed in newborns, depending on the degree of thrombocytopenia. It is recommended that neonates be followed with serial platelet counts for the first few days after birth.,
After initial reports by the Portuguese physician Amato Lusitano in 1556 and Lazarus de la Rivière (physician to the King of France) in 1658, it was the German physician and poet Paul Gottlieb Werlhof who in 1735 wrote the most complete initial report of the purpura of ITP. Platelets were unknown at the time. The name "Werlhof's disease" was used more widely before the current descriptive name became more popular. Platelets were described in the early 19th century, and in the 1880s several investigators linked the purpura with abnormalities in the platelet count. The first report of a successful therapy for ITP was in 1916, when a young Polish medical student, Paul Kaznelson, described a female patient's response to a splenectomy. Splenectomy remained a first-line remedy until the introduction of steroid therapy in the 1950s.
- Cines DB, McMillan R (2005). "Management of adult idiopathic thrombocytopenic purpura". Annu. Rev. Med. 56: 425–42. doi:10.1146/annurev.med.56.082103.104644. PMID 15660520.
- Coopamah M, Garvey M, Freedman J, Semple J (2003). "Cellular immune mechanisms in autoimmune thrombocytopenic purpura: An update". Transfus Med Rev 17 (1): 69–80. doi:10.1053/tmrv.2003.50004. PMID 12522773.
- Schwartz RS (2007). "Immune thrombocytopenic purpura—from agony to agonist". N. Engl. J. Med. 357 (22): 2299–301. doi:10.1056/NEJMe0707126. PMID 18046034.
- Semple JW, Freedman J (1991). "Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia". Blood 78 (10): 2619–25. PMID 1840468.
- Stasi R, Cooper N, Del Poeta G, et al. (August 2008). "Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab". Blood 112 (4): 1147–50. doi:10.1182/blood-2007-12-129262. PMID 18375792.
- Yu J, Heck S, Patel V, et al. (August 2008). "Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura". Blood 112 (4): 1325–8. doi:10.1182/blood-2008-01-135335. PMC 2515134. PMID 18420827.
- Godeau B, Porcher R, Fain O, et al. (August 2008). "Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study". Blood 112 (4): 999–1004. doi:10.1182/blood-2008-01-131029. PMID 18463354.
- Cines DB, Bussel JB (2005). "How I treat idiopathic thrombocytopenic purpura (ITP)". Blood 106 (7): 2244–51. doi:10.1182/blood-2004-12-4598. PMID 15941913.
- "Diagnosis and treatment of idiopathic thrombocytopenic purpura: recommendations of the American Society of Hematology. The American Society of Hematology ITP Practice Guideline Panel". Ann. Intern. Med. 126 (4): 319–26. 1997. doi:10.7326/0003-4819-126-4-199702150-00010. PMID 9036806.
- Liesner RJ, Machin SJ (1997). "ABC of clinical haematology. Platelet disorders". BMJ 314 (7083): 809–12. doi:10.1136/bmj.314.7083.809. PMC 2126215. PMID 9081003.
- Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA (April 2011). "The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia". Blood 117 (16): 4190–207. doi:10.1182/blood-2010-08-302984. PMID 21325604.
- Stevens W, Koene H, Zwaginga JJ, Vreugdenhil G (2006). "Chronic idiopathic thrombocytopenic purpura: present strategy, guidelines and new insights". The Netherlands journal of medicine 64 (10): 356–63. PMID 17122451.
- "Idiopathic thrombocytopenic purpura: Treatments and Drugs". Mayo Clinic. Retrieved October 16, 2012.
- Bussel JB, Kuter DJ, George JN, et al. (2006). "AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP". N. Engl. J. Med. 355 (16): 1672–81. doi:10.1056/NEJMoa054626. PMID 17050891.
- Kuter, DJ; Rummel, M; Boccia, R; Macik, BG; Pabinger, I; Selleslag, D; Rodeghiero, F; Chong, BH; Wang, X; Berger, DP (November 2010). "Romiplostim or standard of care in patients with immune thrombocytopenia". N. Engl. J. Med. 363 (20): 1889–99. doi:10.1056/NEJMoa1002625. PMID 21067381.
- Bussel JB, Cheng G, Saleh MN, et al. (2007). "Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura". N. Engl. J. Med. 357 (22): 2237–2247. doi:10.1056/NEJMoa073275. PMID 18046028.
- "FDA approves Promacta (eltrombopag), the first oral medication to increase platelet production for people with serious blood disorder" (Press release). GlaxoSmithKline. 2008-11-20. Retrieved 2008-11-25.
- See http://www.itpsupport.org.uk/american/%205.%20Splenectomy%20in%20ITP.pdf, page 2.
- Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N, Provan D, Newland A, Amadori S, Bussel JB (2009). "Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review". Blood 113 (6): 1231–40. doi:10.1182/blood-2008-07-167155. PMID 18945961.
- Provan D, Stasi R, Newland AC, et al. (2010). "International consensus report on the investigation and management of primary immune thrombocytopenia". Blood 115 (2): 168–86. doi:10.1182/blood-2009-06-225565. PMID 19846889.
- Godeau B, Durand JM, Roudot-Thoraval F, et al. (1997). "Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases". Br. J. Haematol. 97 (2): 336–9. doi:10.1046/j.1365-2141.1997.412687.x. PMID 9163598.
- Braendstrup P, Bjerrum OW, Nielsen OJ, et al. (2005). "Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura". Am. J. Hematol. 78 (4): 275–80. doi:10.1002/ajh.20276. PMID 15795920.
- Patel V, Mihatov N, Cooper N, Stasi R, Cunningham-Rundles S, Bussel JB (February 2007). "Long-term responses seen with rituximab in patients with ITP" (PDF). Community Oncology 4 (2): 107. doi:10.1016/s1548-5315(11)70061-4.
- Arnold DM, Dentali F, Crowther MA, et al. (January 2007). "Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura". Ann. Intern. Med. 146 (1): 25–33. doi:10.7326/0003-4819-146-1-200701020-00006. PMID 17200219.
- "Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study". Rigel Pharmaceuticals: News Release. Rigel Pharmaceuticals. 11/09/2007. Retrieved 2008-02-11. Check date values in:
- Watts RG (2004). "Idiopathic thrombocytopenic purpura: a 10-year natural history study at the children's hospital of Alabama". Clinical pediatrics 43 (8): 691–702. doi:10.1177/000992280404300802. PMID 15494875.
- Treutiger I, Rajantie J, Zeller B, Henter JI, Elinder G, Rosthøj S (2007). "Does treatment of newly diagnosed idiopathic thrombocytopenic purpura reduce morbidity?". Arch. Dis. Child. 92 (8): 704–7. doi:10.1136/adc.2006.098442. PMC 2083887. PMID 17460024.
- Ou CY, Hsieh KS, Chiou YH, Chang YH, Ger LP (2006). "A comparative study of initial use of intravenous immunoglobulin and prednisolone treatments in childhood idiopathic thrombocytopenic purpur". Acta paediatrica Taiwanica = Taiwan er ke yi xue hui za zhi 47 (5): 226–31. PMID 17352309.
- Nourse, JP (Jan 2012). "The KIR2DS2/DL2 genotype is associated with adult persistent/chronic and relapsed immune thrombocytopenia independently of FCGR3a-158 polymorphisms.". Blood Coagul Fibrinolysis. 23 (1): 45–50.
- Seymour, LA (Mar 2014). "The presence of KIR2DS5 confers protection against adult immune thrombocytopenia.". Tissue Antigens 83 (3): 154–60.
- Cines DB, Blanchette VS (2002). "Immune thrombocytopenic purpura". N. Engl. J. Med. 346 (13): 995–1008. doi:10.1056/NEJMra010501. PMID 11919310.
- "Amgen to Discuss Romiplostim BLA". drugs.com. March 12, 2008. Retrieved 2008-11-04.
- Schoonen WM, Kucera G, Coalson J, et al. (April 2009). "Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database". Br. J. Haematol. 145 (2): 235–44. doi:10.1111/j.1365-2141.2009.07615.x. PMID 19245432.
- Roback et al. AABB Technical Manual, 16th Ed. Bethesda, AABB Press, 2008.
- Webert KE, Mittal R, Sigouin C, Heddle NM, Kelton JG (December 2003). "A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic purpura". Blood 102 (13): 4306–11. doi:10.1182/blood-2002-10-3317. PMID 12947011.
- Mais DD. ASCP Quick Compendium of Clinical Pathology. Chicago: ASCP Press, 2009.
- Stasi R, Newland AC (May 2011). "ITP: a historical perspective". Br. J. Haematol. 153 (4): 437–50. doi:10.1111/j.1365-2141.2010.08562.x. PMID 21466538.
- synd/3349 at Who Named It?
- Liebman HA (2008). "Immune thrombocytopenia (ITP): an historical perspective". Hematology Am Soc Hematol Educ Program 2008 (1): 205. doi:10.1182/asheducation-2008.1.205. PMID 19074083.
- The ITP Foundation - A nonprofit organization dedicated to helping children with Immune Thrombocytopenic Purpura
- ITPeducation.com This educational curriculum is designed to provide evidence-based clinical information on the diagnosis and management of patients with ITP to hematologists, oncologists, and other health care professionals
- Platelet Disorder Support Association A non-profit corporation to provide information, support, and encourage research about ITP and other platelet disorders
- ITP Support Association. A UK registered charity which aims to promote and improve the general welfare of patients, and the families of patients, with Idiopathic Thrombocytopenic Purpura.